Metabolism-based drug interactions involving oral azole antifungals in humans

被引：23

作者：

Benedetti, MS

Bani, M

机构：

[1] UCB Pharma SA, F-92003 Nanterre, France

[2] Zambon Grp SpA, Preclin Dev Dept, I-20091 Milan, Italy

来源：

DRUG METABOLISM REVIEWS | 1999年 / 31卷 / 03期

关键词：

D O I：

10.1081/DMR-100101941

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：665 / 717

页数：53

共 169 条

[21] DISPOSITION OF KETOCONAZOLE, AN ORAL ANTIFUNGAL, IN HUMANS [J].

BRASS, C ;

GALGIANI, JN ;

BLASCHKE, TF ;

DEFELICE, R ;

OREILLY, RA ;

STEVENS, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 21 (01) :151-158

[22] EFFECT OF KETOCONAZOLE ON HEPATIC OXIDATIVE DRUG-METABOLISM [J].

BROWN, MW ;

MALDONADO, AL ;

MEREDITH, CG ;

SPEEG, KV .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (03) :290-297

[23] EFFECT OF FLUCONAZOLE ON PHARMACOKINETICS OF 2',3'-DIDEOXYINOSINE IN PERSONS SEROPOSITIVE FOR HUMAN-IMMUNODEFICIENCY-VIRUS [J].

BRUZZESE, VL ;

GILLUM, JG ;

ISRAEL, DS ;

JOHNSON, GL ;

KAPLOWITZ, LG ;

POLK, RE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) :1050-1053

[24]

Buggia I, 1996, ANTICANCER RES, V16, P2083

[25] Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin [J].

Burkhart, GA ;

Sevka, MJ ;

Temple, R ;

Honig, PK .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (01) :93-96

[26]

Cato A, 1997, DRUG METAB DISPOS, V25, P1104

[27]

Chan JD, 1998, PHARMACOTHERAPY, V18, P1304

[28]

CHANG Y, 1998, J PHARMACOL EXP THER, V287, P246

[29]

ChanTompkins NH, 1997, CLIN INFECT DIS, V24, P1285, DOI 10.1093/clinids/24.6.1285

[30] URINARY METABOLITES OF RIFABUTIN, A NEW ANTIMYCOBACTERIAL AGENT, IN HUMAN VOLUNTEERS [J].

COCCHIARA, G ;

BENEDETTI, MS ;

VICARIO, GP ;

BALLABIO, M ;

GIOIA, B ;

VIOGLIO, S ;

VIGEVANI, A .

XENOBIOTICA, 1989, 19 (07) :769-780

← 1 2 3 4 5 6 7 8 9 10 →